Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05971550
Other study ID # APHP210080
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date September 2023
Est. completion date December 2025

Study information

Verified date February 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Claire Pintado, Dr
Phone +33142494973
Email claire.pintado@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Since the use of antibiotics, Neisseria Gonorrhoeae (NG) has acquired progressive resistance to penicillins, sulfonamides, tetracyclines and quinolones. The oropharynx is recognized as an important site for DNA exchange between NG and other commensal Neisseria, allowing NG to acquire new antimicrobial resistance. Despite the worrying data on the emergence of resistant NG, the recommendations remain to systematically treat these infections with ceftriaxone, including asymptomatic pharyngeal localizations. The objective of our study is to evaluate a ceftriaxone sparing strategy in order to limit the emergence of antibiotic resistance. The primary objective of the study is to evaluate the clearance of Neisseria gonorrhoeae, 3 months after the diagnosis of asymptomatic pharyngeal carriage documented on nucleic acid amplification test (NAAT).


Description:

Non-inferiority, multicenter, prospective, randomized open-label study, in two parallel arms, comparing the pharyngeal clearance of Neisseria gonorrhoeae (NG) at 3 months with or without treatment with ceftriaxone. Experimental group: Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to Sexually Transmitted Infection or positive Polymerase chain reaction (PCR) at 3 months) Control group: Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal Polymerase chain reaction (PCR) again positive for NG during follow-up.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 254
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Patients (n=154): Patient inclusion criteria : - Adult patient (age = 18 years old) - Patient consulting for a pharyngeal Neisseria gonorrhoeae Sexually Transmitted Infection (STI) and meeting the following criteria : - Positive sample for NAAT by PCR in the pharynx for Neisseria gonorrhoeae dating back a maximum of 7 days (the date of the sample and those of inclusion will be compared) and - asymptomatic patient - Absence of symptoms of other bacterial STIs or other asymptomatic bacterial STIs confirmed on the systematic screening assessment carried out within 7 days before inclusion - Patient's agreement to use protection or abstinence from all oral sex for 3 months follow-up (experimental group) or for 7 days (control group) - For men whose female partner(s) are of childbearing age and for women of childbearing age: use of effective contraception (failure rate less than 1% per year) throughout research - Patient benefiting from a social health security scheme - Patient having signed a free and informed consent Patients non-inclusion criteria : - Minor patient - Symptomatic patient in the pharynx - Presence of symptoms of another bacterial STI or of an asymptomatic bacterial STI confirmed on the screening report carried out within 7 days before inclusion - Antibiotic treatment that may be active on Neisseria gonorrhoeae (C3G, Fluoroquinolones, Macrolides, Cyclins, Aminosides, Penicillins) within 14 days before inclusion - Hypersensitivity to ceftriaxone, other cephalosporins or to any of the excipients - History of severe hypersensitivity (e.g. anaphylactic reaction) to another class of antibacterial agents of the beta-lactam family (penicillins, monobactams and carbapenems). - Contraindication to ceftriaxone - Contraindication to intramuscular injections - Person under legal protection, under guardianship or curatorship, person deprived of liberty, under safeguard of justice, subject to psychiatric care, under duress, admitted to a health or social establishment for purposes other than those of research - Pregnant or breastfeeding woman - Lack of social health insurance - Patient included in another interventional study Partners (n=100) : Partner Inclusion Criteria : - Sexual contact of the index case (genito-anal or genito-vaginal, oro-genital or oro-anal or oro-oral relations) in the month preceding the inclusion of the index case - Adult patient (age = 18 years old) - Patient benefiting from a social health security scheme - Patient having signed a free and informed consent Partner non-inclusion Criteria: - Minor patient - Person under legal protection, under guardianship or curatorship, person deprived of liberty, under safeguard of justice, subject to psychiatric care, under duress, admitted to a health or social establishment for purposes other than those of research - Patient included in another interventional study - Pregnant or breastfeeding woman

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Absence of antibiotic treatment
Absence of antibiotic treatment for at most 3 months after screening for asymptomatic NG pharyngeal infection (treatment if onset of symptoms related to STI or positive PCR at 3 months)
Drug:
Ceftriaxone
Ceftriaxone 1000 mg by parenteral intramuscular route, in a single dose, according to the national recommendations in force, to be repeated if pharyngeal PCR again positive for NG during follow-up

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with a negative pharyngeal nucleic acid amplification test (NAAT) for Neisseria gonorrhoeae (NG) 3 months after inclusion
Secondary Proportion of patients with a negative pharyngeal nucleic acid amplification test (NAAT) and a negative pharyngeal culture for Neisseria gonorrhoeae (NG) at 1 month after inclusion
Secondary Proportion of patients with negative pharyngeal NG cultures at 3 months after inclusion
Secondary Proportion of patients carrying methicillin-resistant Staphylococcus aureus (MRSA) Impact of ceftriaxone on the carriage of methicillin-resistant Staphylococcus aureus (MRSA) on the pharyngeal sample at 1 month after inclusion
Secondary Proportion of patients carrying extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae Impact of ceftriaxone on the carriage of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae on the anal sample at 1 month after inclusion
Secondary Proportion of patients carrying methicillin-resistant Staphylococcus aureus (MRSA) Impact of ceftriaxone on the carriage of methicillin-resistant Staphylococcus aureus (MRSA) on the pharyngeal sample and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae on the anal sample at 3 months after inclusion
Secondary Proportion of patients carrying extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae Impact of ceftriaxone on the carriage of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae on the anal sample at 3 months after inclusion
Secondary Proportion of patients with spontaneous pharyngeal clearance of NG Analysis of factors associated with spontaneous pharyngeal clearance of NG :
Socio-demographic and behavioural characteristics
Amount of NG in the pharynx assessed by exploratory semi-quantitative PCR
Bactericidal activity of anti-gonococcal antibodies and the production of specific anti-gonococcal antibodies in pharyngeal secretions
at 1 month after inclusion
Secondary Proportion of patients with spontaneous pharyngeal clearance of NG Analysis of the factors associated with spontaneous pharyngeal clearance of NG :
Socio-demographic and behavioural characteristics
Amount of NG in the pharynx assessed by exploratory semi-quantitative PCR
Bactericidal activity of anti-gonococcal antibodies and the production of specific anti-gonococcal antibodies in pharyngeal secretions
at 3 months after inclusion
Secondary Proportion of partners with NAAT positive for NG Proportion of partners with NAAT positive for NG on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) At inclusion of the partner
Secondary Proportion of partners with NG cultures positive Proportion of partners with NG cultures positive on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) At inclusion of the partner
Secondary Proportion of partners with NAAT positive for NG Proportion of partners with NAAT positive for NG on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) at 1 month after inclusion of the partner
Secondary Proportion of partners with NG cultures positive Proportion of partners with NG cultures positive on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) at 1 month after inclusion of the partner
Secondary Proportion of partners with NAAT positive for NG Proportion of partners with NAAT positive for NG on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) at 3 months after inclusion of the partner
Secondary Proportion of partners with NG cultures positive Proportion of partners with NG cultures positive on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) at 3 months after inclusion of the partner
Secondary Proportion of identical genome between partner and patient Up to 3 months
Secondary Proportion of patients with Resistant NG strains Up to 3 months
Secondary Proportion of partners with Resistant NG strains Up to 3 months
Secondary Proportion of adverse events Up to 3 months
See also
  Status Clinical Trial Phase
Completed NCT04269434 - GonoScreen: Efficacy of Screening STIs in MSM N/A
Completed NCT04094883 - Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine Phase 4
Completed NCT01733069 - Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHERâ„¢ System N/A
Completed NCT00978848 - Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing N/A
Recruiting NCT05286931 - SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection N/A
Completed NCT01329588 - Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers Phase 4
Not yet recruiting NCT06369220 - A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections N/A
Completed NCT05216744 - Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection Phase 2
Recruiting NCT05581160 - Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST) N/A
Completed NCT02870101 - Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT N/A